Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:GILD News 6 December 2025 - 28 January 2026

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Gilead Sciences shares rose 2.3% to $140.97 Tuesday, hitting a 52-week high after Medicare named its HIV drug Biktarvy for price negotiations starting in 2028. Trading volume topped 10.5 million shares. CEO Daniel O’Day sold 115,640 shares last week under a pre-set plan. Gilead will report fourth-quarter and full-year results after markets close on Feb. 10.
28 January 2026
···
Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead Sciences shares rose 1.8% to $140.24 Tuesday afternoon, hitting a 12-month high of $141.69 earlier in the session. Citi, Truist, and BMO raised price targets following upbeat analyst notes and strong momentum for the company’s HIV prevention drug Yeztugo. Investors await early February results and Gilead’s earnings, expected around Feb. 10.
27 January 2026
···
Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead Sciences shares closed at a 52-week high of $137.78 on Monday, up 1.36% for a fourth straight gain. CEO Daniel O’Day sold $15.6 million in stock under a pre-set plan, according to an SEC filing. BMO and UBS raised their price targets, citing momentum in HIV drugs and new coverage for Yeztugo. Trading volume exceeded normal levels as the stock outperformed major pharma peers.
27 January 2026
··
Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead Sciences shares rose 0.9% to $137.21 midday Monday after BMO Capital Markets raised its price target to $150, citing expanded insurance coverage for Yeztugo, Gilead’s new HIV prevention shot. CVS confirmed coverage starting Jan. 1, pushing overall insurer coverage above 80%. Gilead says it has already met its 2025 Yeztugo sales target of $150 million. Investors await Gilead’s earnings report, expected Feb. 10.
26 January 2026
·
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead Sciences shares rose 3.65% to $135.93 after Phase 3 trial results showed Trodelvy plus Keytruda cut the risk of breast cancer progression or death by 35% versus Keytruda and chemotherapy. The company has submitted regulatory filings in the U.S. and Europe. CEO Daniel O’Day plans to sell up to $15.6 million in shares. Investors await Gilead’s earnings report on Feb. 10.
24 January 2026
·
Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead Sciences shares slipped 0.2% to $124.68 Tuesday, outperforming a broader market drop. Bernstein reiterated its Outperform rating and $135 target, citing Yeztugo as a key 2026 driver. Florida announced steep cuts to its AIDS Drug Assistance Program, drawing criticism from advocates and raising concerns over HIV drug access.
20 January 2026
··
Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead Sciences shares closed up 0.15% at $124.91 on Monday after Bernstein said new Medicaid drug-pricing rules would have limited impact on its HIV drug Biktarvy. Bernstein estimated less than $200 million in 2026 revenue impact for older HIV drugs Genvoya and Odefsey. Investors await more details from the Trump administration’s pricing rollout and Gilead’s update at the J.P. Morgan Healthcare Conference in January.
30 December 2025
·
Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025

Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025

Gilead Sciences shares closed up 0.83% at $125.19 on Dec. 23, 2025, then held steady after hours. The company announced it will exclusively license Assembly Biosciences’ herpes drug candidates, expanding its antiviral pipeline. U.S. markets will close early on Dec. 24, with thin trading expected. Investors are watching for headlines and Gilead’s upcoming J.P. Morgan Healthcare Conference appearance.
24 December 2025
·
Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open

Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open

Gilead Sciences closed Monday at $124.16, down 0.10%, and edged up to $124.35 after hours. The company announced it will exclusively license Assembly Biosciences’ herpes simplex virus drug candidates, paying $35 million upfront with potential milestones up to $330 million. Volume for the session was about 6.52 million shares. Market cap stood near $154 billion.
23 December 2025
·
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences said Monday it will license Assembly Biosciences’ investigational herpes simplex virus programs, including two oral candidates, for a $35 million payment. The move expands Gilead’s antiviral pipeline days after it joined a Trump administration drug-pricing deal. Shares traded around $123–$124, slightly lower on the day. No new HSV therapies have been approved in the U.S. or Europe for over 25 years.
22 December 2025
·
Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025

Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025

Gilead Sciences shares traded near $124.29, up 2.35% premarket Monday, after the company signed a three-year U.S. drug-pricing agreement and reported late-stage HIV pipeline progress. The deal includes discounts on key medicines and a direct-to-patient program, with Gilead expecting a manageable financial impact. Shares remain close to their 52-week high of $128.70.
22 December 2025
·
Gilead Sciences (GILD) Stock Week-Ahead Outlook: Pricing Deal Shockwave, HIV Pipeline Momentum, and Key Catalysts for Dec 22–26, 2025

Gilead Sciences (GILD) Stock Week-Ahead Outlook: Pricing Deal Shockwave, HIV Pipeline Momentum, and Key Catalysts for Dec 22–26, 2025

Gilead Sciences shares closed near $124.29 ahead of Christmas week as investors reacted to a new U.S. drug-pricing deal announced Dec. 19 and positive late-stage HIV trial results. The company expects manageable financial impact from Medicaid discounts and new pricing commitments. Gilead reported its investigational HIV regimen matched Biktarvy in Phase 3 results, with no major safety issues.
21 December 2025
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences shares closed at $124.29 on Dec. 19, up 2.32%, after President Trump announced a drug pricing deal with nine major firms, including Gilead. The agreement includes Medicaid price cuts, cash-pay discounts via TrumpRx.gov, and a three-year tariff exemption tied to increased U.S. manufacturing. Gilead expects the financial impact to be manageable in 2026.
20 December 2025
··
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences Stock (GILD) After Hours on Dec. 19, 2025: TrumpRx Pricing Deal, UK Lenacapavir Approval, and What to Watch Before the Next Market Open

Gilead Sciences, Inc. (NASDAQ: GILD) ended Friday, December 19, 2025, with a sharp, high-volume move that kept traders focused into the after-hours session. The headline drivers were a new U.S. government pricing agreement tied to TrumpRx.gov and tariff relief, plus a fresh U.K. regulatory approval for lenacapavir—two catalysts that hit the tape on the same day and helped explain why Gilead was among the stronger large-cap pharma names into the close. Gilead stock price recap after the bell (Dec. 19 close + after-hours) Gilead’s regular session finished firmly higher, and the after-hours tape stayed constructive but calm. One notable detail:
20 December 2025
··
Gilead Sciences (GILD) Stock Today: Price, Fresh News and Analyst Outlook on December 8, 2025

Gilead Sciences (GILD) Stock Today: Price, Fresh News and Analyst Outlook on December 8, 2025

As of Monday, December 8, 2025, Gilead Sciences, Inc. (NASDAQ: GILD) sits near the upper end of its 52‑week range, supported by strong HIV franchises, new long‑acting prevention drugs, high‑profile cancer data at ASH 2025 and a steady dividend. At the same time, investors are weighing slowing COVID‑19 sales, competitive oncology pressures and policy risk. Below is a structured look at today’s price action, the latest news flow dated December 8, 2025, analyst forecasts and the medium‑term investment narrative around Gilead Sciences stock. Gilead Sciences (GILD) stock price on December 8, 2025 Gilead shares are trading around $121 per share
8 December 2025
Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (NASDAQ: GILD) heads into Monday’s session riding an event‑packed weekend: new cancer data at the ASH 2025 hematology meeting, fresh institutional‑ownership filings, and another round of valuation work from analysts and quant platforms. Here’s what investors should know about Gilead Sciences stock before the U.S. market opens on Monday, December 8, 2025. 1. Price action: defensive biotech near the top of its range As of the close on Friday, December 5, Gilead Sciences stock finished at $121.22, about 1.14% lower on the day; after‑hours trading nudged it slightly higher to ~$121.34. TechStock² At that level: Several recent analyses
8 December 2025
··
Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences stock (NASDAQ: GILD) is trading near the upper end of its 52‑week range as of early December 2025, supported by stronger guidance, big HIV and liver franchises, and a mixed but important year for its oncology pipeline. At the same time, new deals in cell therapy and targeted protein degradation show management leaning into long‑term cancer bets, even at the cost of a bit of near‑term EPS. Here’s a detailed look at the latest price action, earnings, drug news, analyst forecasts and key risks that matter for GILD into 2026. Gilead Sciences stock price and recent trading As
6 December 2025
···
1 2

Stock Market Today

Cambricon Class A stock price dips again: what to watch next for China AI chip name 688256

Cambricon Class A stock price dips again: what to watch next for China AI chip name 688256

8 February 2026
Cambricon Technologies shares closed at 1,036.99 yuan in Shanghai on Friday, down 2.02%, with volume at about 8 million shares. The stock has fallen roughly 16.5% since Feb. 2 after sharp declines earlier in the week. Investors await the company’s next earnings report, due March 13, for confirmation of its forecasted profit turnaround. Cambricon is valued at about 437.28 billion yuan.
Infineon stock in focus after Friday rise as reports flag April price hikes for power chips

Infineon stock in focus after Friday rise as reports flag April price hikes for power chips

8 February 2026
Infineon shares closed up 1.5% at 42.04 euros Friday on Xetra after reports the company plans April price hikes on some power products. TrendForce said the increases, citing tight supply and higher costs, would apply from April 1. The Feb. 12 record date and Feb. 19 annual meeting are next for shareholders. UBS raised its price target to 47 euros, citing stronger margins.
TE Connectivity stock jumps 3.5% into the weekend — what to watch for TEL next week

TE Connectivity stock jumps 3.5% into the weekend — what to watch for TEL next week

8 February 2026
TE Connectivity (NYSE: TEL) closed Friday up 3.46% at $215.91, rebounding after a 3.29% drop Thursday, but remains 5% lower for the week and 14% below its 52-week high. The company expects to close a $750 million senior notes offering on Monday and pay a $0.71 dividend March 13. Investors await Friday’s U.S. CPI report, seen as a key market driver.
Go toTop